http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2001502702-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S930-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0004 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 |
| filingDate | 1997-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2001-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2001502702-A |
| titleOfInvention | Use of LH-RH antagonists as diagnostics |
| abstract | (57) [Summary]nThe present invention relates to diagnostic agents for improving the efficacy of hysteroscopy characterized by LH-RH antagonists, in particular cetrorelix content. This medicament is intended for application before hysteroscopy and / or for preoperative medication, also in a single dose of 0.1 to 2 mg / kg. However, for applications prior to hysteroscopy and / or for preparation for surgery, several doses of 0.01-0.5 mg / kg body weight are given, preferably divided over 1-14 days. . Furthermore, the medicament is suitable for use in conjunction with treatment of subsequent uterine disease states in hysteroscopy, such as fibroids and endometrial hyperplasia. |
| priorityDate | 1996-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 31.